# Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer

> **NCT00422773** · PHASE1,PHASE2 · COMPLETED · sponsor: **Technische Universität Dresden** · enrollment: 21 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT00422773
- **Lead sponsor:** Technische Universität Dresden
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-06
- **Final completion:** —
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2009-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00422773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00422773, "Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00422773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*